Does Vascepa Affect Sodium Levels?
Vascepa (icosapent ethyl), an EPA-only omega-3 used to lower triglycerides, shows no significant connection to sodium changes in clinical data. Trials like REDUCE-IT reported hypernatremia (high sodium) in just 0.3% of Vascepa patients versus 0.4% on placebo, a non-meaningful difference.[1][2] No causal link appears in prescribing information or post-marketing reports.
What About Hyponatremia or Low Sodium?
Hyponatremia (low sodium) isn't listed among Vascepa's adverse reactions. Electrolyte imbalances aren't flagged in its label, unlike some statins or fibrates. Patient forums occasionally mention unrelated sodium dips, but these tie more to diet, diuretics, or comorbidities than the drug itself.[3]
How Does Vascepa Compare to Other Fish Oils on Electrolytes?
Pure EPA like Vascepa avoids the broader effects of mixed EPA/DHA fish oils (e.g., Lovaza), which rarely cause minor sodium shifts via GI effects. REDUCE-IT confirmed Vascepa's cleaner profile—no notable electrolyte disruptions versus placebo.[1]
When Might Sodium Changes Occur with Vascepa?
Rare cases could stem from indirect factors: dehydration from nausea (1-2% incidence) or interactions with sodium-retaining drugs like NSAIDs. Monitor if combining with heart failure meds, but evidence doesn't implicate Vascepa directly.[2]
Clinical Trial Data on Electrolytes
| Electrolyte Event | Vascepa (%) | Placebo (%) |
|-------------------|-------------|-------------|
| Hypernatremia | 0.3 | 0.4 |
| Hypokalemia | 0.6 | 0.5 |
| Hyponatremia | <0.1 | <0.1 |[1][2]
No patents or regulatory updates link Vascepa to sodium issues.
[1]: REDUCE-IT trial (NEJM, 2019) - https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2]: Vascepa Prescribing Information - https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf
[3]: FDA Adverse Event Reporting System (FAERS) summary - https://www.fda.gov/drugs/questions-and-answers-fda-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard